Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

UNC's Gedas Bertasius uses basketball to train computers
Today, the same instincts that once helped Gedas Bertasius scan a basketball court — where the pass is headed, how the defense might collapse —...
Tue Mar 31, 2026

Carolina Across 100 launches final program
UNC-Chapel Hill’s Carolina Across 100 initiative welcomes 10 teams covering 19 counties to its final program Our State, Our Future. This culminating program marks the...
Tue Mar 31, 2026

Interview with comedian, UNC alum Lewis Black
Lewis Black, the now 77-year-old stand-up legend has retired from touring, and his recent “Goodbye Yeller Brick Road” performances were his last. But Black, the...
Mon Mar 30, 2026

Here are 5 things I love about Carolina
Rameses at Home - One of my favorite experiences in the community is when I drive past the Hogan family farm and I catch a...
Sat Mar 28, 2026